Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.44 |
| ▸ | GPR3 | P46089 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL39179 | 1.00 | CA1 (0.44) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL6659829 | 1.00 | CA1 (0.44) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL28543595 | 0.96 | CA1 (0.41) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL8639691 | 0.96 | CA1 (0.41) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL25292878 | 0.92 | CA1 (0.44) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL25292546 | 0.92 | GPR3 (0.48) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL25285896 | 0.92 | CA1 (0.44) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL25287606 | 0.92 | CA1 (0.44) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL20570425 | 0.92 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL893770 | 0.92 | CA1 (0.44) | CA1CA2CA7CA13GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195463-A1 | ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE | FACULDADE DE CIENCIAS DA UNIV DE LISBOA (PT) | 2025-06-19 | — | — | US | claimed |
| EP-4508058-A1 | ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE | Faculdade de Ciencias da Universidade de Lisboa (PT) | 2025-02-19 | — | — | EP | claimed |
| WO-2023199134-A1 | ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE | FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA (PT) | 2023-10-19 | — | — | WO | claimed |
| US-20020049190-A1 | Pharmaceutical compositions comprising metal complexes | ANORMED INC. (CA) | 2002-04-25 | — | — | US | claimed |
| EP-1163247-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING METAL COMPLEXES | ANORMED INC. (CA) | 2001-12-19 | — | — | EP | claimed |
| WO-2000056743-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING METAL COMPLEXES | ANORMED INC. (CA) | 2000-09-28 | — | — | WO | claimed |
| US-20250195463-A1 | ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE | FACULDADE DE CIENCIAS DA UNIV DE LISBOA (PT) | 2025-06-19 | — | — | US | disclosed |
| US-20250186457-A1 | USE OF AN ORGANOMETALLIC RUTHENIUM COMPOUND FOR THE PREVENTION AND/OR TREATMENT OF DISEASES AND/OR CONDITIONS RELATED TO CANCER IN AN INDIVIDUAL | FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA (PT) | 2025-06-12 | — | — | US | disclosed |
| EP-4508058-A1 | ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE | Faculdade de Ciencias da Universidade de Lisboa (PT) | 2025-02-19 | — | — | EP | disclosed |
| EP-4482499-A1 | USE OF AN ORGANOMETALLIC RUTHENIUM COMPOUND FOR THE PREVENTION AND/OR TREATMENT OF DISEASES AND/OR CONDITIONS RELATED TO CANCER IN AN INDIVIDUAL | Faculdade de Ciencias da Universidade de Lisboa (PT) | 2025-01-01 | — | — | EP | disclosed |
| CN-118785914-A | Use of organometallic ruthenium compounds for the prevention and/or treatment of cancer-related diseases and/or disorders in an individual | 科学学院里斯本大学 | 2024-10-15 | — | — | CN | disclosed |
| WO-2023199134-A1 | ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE | FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA (PT) | 2023-10-19 | — | — | WO | disclosed |
| US-20230285945-A1 | CATALYST CONTAINING ACTIVATED CARBON ADSORBED WITH RUTHENIUM COMPLEX, AND METHOD FOR PRODUCING REDUCTION PRODUCT USING SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2023-09-14 | — | — | US | disclosed |
| EP-4115975-A1 | CATALYST CONTAINING ACTIVATED CARBON ON WHICH RUTHENIUM COMPLEX IS ADSORBED, AND METHOD FOR PRODUCING REDUCTION PRODUCT USING SAME | Takasago International Corporation (JP) | 2023-01-11 | — | — | EP | disclosed |
| CN-115209993-A | Catalyst comprising activated carbon having ruthenium complex adsorbed thereon and method for producing reduced product using same | 高砂香料工业株式会社 | 2022-10-18 | — | — | CN | disclosed |
| CN-107466297-B | Macromolecular transition metal complex for treating cancer and preparation method thereof | 科学学院里斯本大学 | 2020-10-30 | — | — | CN | disclosed |
| CN-1852882-A | Process for reduction of carbon dioxide with organometallic complex | JAPAN SCIENCE & TECH AGENCY (JP) | 2006-10-25 | — | — | CN | disclosed |
| US-20020049190-A1 | Pharmaceutical compositions comprising metal complexes | ANORMED INC. (CA) | 2002-04-25 | — | — | US | disclosed |
| EP-1163247-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING METAL COMPLEXES | ANORMED INC. (CA) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000056743-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING METAL COMPLEXES | ANORMED INC. (CA) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285945-A1 | CATALYST CONTAINING ACTIVATED CARBON ADSORBED WITH RUTHENIUM COMPLEX, AND METHOD FOR PRODUCING REDUCTION PRODUCT USING SAME | RRS1, POR, SCO2 | CA1 400/4885CA2 244/4885CA7 158/4885 |
| US-20250195463-A1 | ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE | SAMM50, CYP4F2, ABCB1 | CA1 1718/4885CA2 869/4885CA7 902/4885 |
| US-20020049190-A1 | Pharmaceutical compositions comprising metal complexes | CFD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F12 | CA1 1271/4885CA2 478/4885CA7 579/4885 |
| US-20250186457-A1 | USE OF AN ORGANOMETALLIC RUTHENIUM COMPOUND FOR THE PREVENTION AND/OR TREATMENT OF DISEASES AND/OR CONDITIONS RELATED TO CANCER IN AN INDIVIDUAL | BRCA1, FH, CLIC4 | CA1 868/4885CA2 1338/4885CA7 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.